May 2025

Alvotech and Advanz Pharma have announced an expansion of their strategic commercial partnership to include three additional biosimilar candidates in Europe. This action strengthens their combined presence in one of the most active biosimilar marketplaces in the globe. Key Highlights of the Agreement: Market Impact: This expansion increases the total number of biosimilars under the…

Biogen Inc. and City Therapeutics, Inc., a pioneer in next-generation RNAi, have formed a strategic research partnership to develop RNA interference (RNAi)-based therapeutics for central nervous system (CNS) disorders. Deal Highlights: City Therapeutics’ innovative RNAi trigger engineering and Biogen’s global medication development and commercialization capabilities are combined in this high-impact collaboration. The initial focus will…